Influenza virus vaccines: lessons from the 2009 H1N1 pandemic
- 30 August 2011
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Virology
- Vol. 1 (4), 254-262
- https://doi.org/10.1016/j.coviro.2011.08.002
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trialThe Lancet Infectious Diseases, 2011
- Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccineProceedings of the National Academy of Sciences of the United States of America, 2011
- AS03A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of AgeClinical Infectious Diseases, 2010
- Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 monthsVaccine, 2010
- Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trialThe Lancet, 2010
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineNew England Journal of Medicine, 2009
- Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in HumansScience, 2009
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in HumansNew England Journal of Medicine, 2009
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972